GO:0016256 N-glycan processing to lysosome Guide

N-glycan processing to lysosome (GO:0016256) is the biological process in which high-mannose N-glycans on newly synthesized glycoproteins are modified by UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase and then trimmed to expose mannose-6-phosphate (M6P) within the ER-Golgi apparatus. This modification is the canonical sorting signal that directs soluble acid hydrolases from the secretory pathway to the lysosome, and it is therefore central to lysosomal homeostasis and to the molecular pathology of lysosomal storage disorders. The same processing machinery also participates in quality-control decisions, because N-glycan status helps select ERAD-resistant misfolded proteins for ER-to-lysosome-associated degradation (ERLAD). For researchers, GO:0016256 is a convergence point for glycobiology, membrane trafficking, lysosomal biology and protein quality control. Defects in M6P generation cause misrouting of multiple hydrolases and underlie mucolipidosis II and III, while altered N-glycan processing has been linked to enzyme activation states such as that of acid alpha-glucosidase. Beyond biosynthesis, endolysosomal N-glycan trimming is critical for the most active form of GAA, indicating that processing continues after delivery to the endolysosomal system. N-glycan remodelling also accompanies MHC-II immunopeptide presentation, expanding the functional reach of this pathway into antigen presentation. Because the pathway is defined by enzymatic steps, it is highly amenable to CRISPR-based causal genetics. Knockout of GNPTAB, GNPTG or NAGPA abolishes or alters M6P tagging, point mutations can separate catalytic from recognition functions, and knock-in reporters can track cargo flux. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0016256, its genes, mechanisms, disease links and experimental models.

GO:0016256 (N-glycan processing to lysosome) is defined as the modification of high-mannose N-glycans by UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase and the subsequent removal of the N-acetylglucosamine residues yielding mannose-6-P, occurring in the ER-Golgi apparatus on N-glycans destined for the lysosome. In simpler terms, it is the two-step enzymatic tagging of lysosome-bound glycoproteins with mannose-6-phosphate, the signal that ensures they are sorted to lysosomes rather than secreted.

GO:0016256 is important because it defines the enzymatic route that creates the mannose-6-phosphate sorting signal for lysosomal enzymes, and its disruption causes misrouting of acid hydrolases with broad consequences for lysosomal storage diseases. The pathway also intersects with protein quality control, since N-glycan processing selects ERAD-resistant misfolded proteins for ER-to-lysosome-associated degradation. In addition, endolysosomal N-glycan processing is required for acid alpha-glucosidase to reach its most active form, linking this GO term to enzyme replacement and Pompe disease research. N-glycan remodelling during MHC-II immunopeptide presentation further connects the pathway to adaptive immunity.

The following genes and proteins are directly or mechanistically associated with N-glycan processing to lysosome (GO:0016256) and its related quality-control and trafficking functions.

Regulation of N-glycan processing to lysosome is embedded in the secretory pathway quality-control network. Glucosidase II and MRH-domain-containing proteins modulate N-glycan trimming and folding decisions in the ER, thereby influencing which glycoproteins proceed through processing. N-glycan status also determines selection of ERAD-resistant misfolded proteins for ER-to-lysosome-associated degradation, providing a quality-control layer that can divert cargo away from normal sorting. In addition, endolysosomal N-glycan processing is required for acid alpha-glucosidase to attain its most active form, indicating that post-delivery processing can regulate enzyme activity states. N-glycan remodelling during MHC-II immunopeptide presentation further shows that processing is tuned in cell-type-specific immune contexts.

Because GO:0016256 generates the mannose-6-phosphate sorting signal, defects in this pathway cause misrouting of multiple acid hydrolases, a hallmark of mucolipidosis II and III. The enzymatic steps catalyzed by GlcNAc-phosphotransferase and the uncovering enzyme are directly implicated in these disorders. Studying GNPTAB, GNPTG and NAGPA variants in CRISPR models can clarify genotype-phenotype relationships.

Endolysosomal N-glycan processing is critical to attain the most active form of acid alpha-glucosidase, the enzyme deficient in Pompe disease. This links GO:0016256 to disease mechanisms beyond sorting, including enzyme maturation and activity. It also suggests that glycan-processing status may influence therapeutic enzyme performance.

N-glycan processing selects ERAD-resistant misfolded proteins for ER-to-lysosome-associated degradation, a pathway relevant to neurodegenerative proteinopathies. The role of N-glycans and their processing in ERLAD of disease-causing mutant Neuroserpin provides a direct neurodegeneration link. Glucosidase II and MRH-domain proteins further connect secretory pathway quality control to disease-relevant proteostasis.

Profound N-glycan remodelling accompanies MHC-II immunopeptide presentation, indicating that glycan-processing pathways shape adaptive immune responses. This connection suggests that genes in GO:0016256 may influence immunopeptidome composition. It also motivates immunology-focused CRISPR screens targeting glycan-processing enzymes.

Mass spectrometry-based glycomics and M6P-specific lectin or antibody assays can quantify the products of GO:0016256. These methods are used to assess whether knockout or point mutations in GNPTAB, GNPTG or NAGPA alter mannose-6-phosphate formation. They provide direct biochemical readouts of pathway activity.

Fluorescence imaging of lysosomal markers and tagged hydrolases can reveal misrouting when M6P tagging is defective. Imaging also captures lysosomal exocytosis events linked to MYO18B and focal adhesion maturation. Co-localization studies with M6P receptors report on sorting fidelity.

Proteomics can identify hydrolases whose secretion versus lysosomal delivery shifts upon pathway perturbation. Immunopeptidomics is suited to test how N-glycan remodelling affects MHC-II immunopeptide presentation. These approaches connect molecular changes to system-level phenotypes.

ERLAD assays monitor delivery of ERAD-resistant misfolded proteins to lysosomes and their dependence on N-glycan processing. Mutant Neuroserpin provides a disease-relevant ERLAD cargo for such studies. Glucosidase II and MRH-domain proteins can be probed as quality-control modifiers.

Researchers studying N-glycan processing to lysosome-related genes often need to determine whether a candidate gene is causally involved in M6P tagging, hydrolase sorting or ERLAD, and CRISPR-based models provide the cleanest route to that causal evidence. EDITGENE supports this work with knockout, point-mutation, knock-in, tagged knock-in and overexpression cell models, together with CRISPR library screening and bioinformatics services tailored to glycan-processing and lysosomal biology.

GO:0016256 (N-glycan processing to lysosome) defines the two-step enzymatic tagging of lysosome-destined N-glycans with mannose-6-phosphate, a signal essential for hydrolase sorting and lysosomal function. Its reach extends to protein quality control through ERLAD, to hydrolase activation in the endolysosomal system, and to immune presentation via N-glycan remodelling. CRISPR-based knockout, point-mutation, knock-in and overexpression models provide the causal toolkit needed to dissect these mechanisms and their disease relevance.